Skip to main content
Top
Published in: Clinical & Experimental Metastasis 5/2008

01-09-2008 | Research Paper

Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone deposition

Authors: N. Patrick McCabe, Maria Madajka, Amit Vasanji, Tatiana V. Byzova

Published in: Clinical & Experimental Metastasis | Issue 5/2008

Login to get access

Abstract

The molecular mechanisms associated with prostate cancer (PCa) progression within bone remain a topic of intense investigation. With the availability of transgenic mouse strains, a model of PCa for use in immune competent/transgenic mice would be highly beneficial. This study was designed to explore the utility of RM1 mouse PCa cells in investigations of tumor:bone interactions. The efficacies of several implantation techniques were examined for reliably producing intra-bone RM1 tumor growth and bone lesion formation in immune competent mice. Longitudinal monitoring of bone remodeling and lesion phenotypes was conducted by microcomputed tomography (μCT) and histological analyses. Our results indicate that direct intrabone injections of RM1 cells are necessary for tumor growth within bone and direct implantation promotes the rapid development of osteolytic bone lesions with periosteal bone deposition post-cortical breach. In vitro, RM1 cells promote the proliferation of osteoblast (MC3T3-E1) and osteoclast (Raw264.7) progenitors in a dose dependent manner. Conditioned culture media from RM1 cells appears to promote earlier expression of genes/proteins associated with osteoblastic differentiation. While clearly stimulating osteoclast function in vivo, RM1 cells had little effect on differentiation and tartate resistant acid phosphatase (TRAP) expression by Raw264.7 cells. These data, coupled with in vivo μCT images, indicate the ability of RM1 cells to induce mixed, yet predominentally osteolytic, responses in bone and illustrate the potential of RM1 cells as a model of investigating prostate tumor:stroma interactions in immune competent/transgenic mice on a C57BL/6 background.
Appendix
Available only for authorised users
Literature
1.
go back to reference American Cancer Society (2007) Cancer facts & figures 2007. American Cancer Society, Inc., Atlanta American Cancer Society (2007) Cancer facts & figures 2007. American Cancer Society, Inc., Atlanta
5.
go back to reference Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML, Matusik RJ (1998) Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 78:319–333PubMed Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML, Matusik RJ (1998) Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 78:319–333PubMed
6.
go back to reference Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, Sangiorgi FO, Maxson RE, Sucov HM, Roy-Burman P (2001) Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101:61–69. doi:10.1016/S0925-4773(00)00551-7 PubMedCrossRef Wu X, Wu J, Huang J, Powell WC, Zhang J, Matusik RJ, Sangiorgi FO, Maxson RE, Sucov HM, Roy-Burman P (2001) Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101:61–69. doi:10.​1016/​S0925-4773(00)00551-7 PubMedCrossRef
7.
9.
go back to reference Grant JF, Iwasawa T, Sinn HW, Siemens DR, Griffith TS, Takacs EB, Ratliff TL (2006) Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-alpha combination therapy. Int J Cancer 119:2632–2641. doi:10.1002/ijc.22220 PubMedCrossRef Grant JF, Iwasawa T, Sinn HW, Siemens DR, Griffith TS, Takacs EB, Ratliff TL (2006) Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-alpha combination therapy. Int J Cancer 119:2632–2641. doi:10.​1002/​ijc.​22220 PubMedCrossRef
10.
go back to reference Griffith TS, Kawakita M, Tian J, Ritchey J, Tartaglia J, Sehgal I, Thompson TC, Zhao W, Ratliff TL (2001) Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses. J Natl Cancer Inst 93:998–1007. doi:10.1093/jnci/93.13.998 PubMedCrossRef Griffith TS, Kawakita M, Tian J, Ritchey J, Tartaglia J, Sehgal I, Thompson TC, Zhao W, Ratliff TL (2001) Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses. J Natl Cancer Inst 93:998–1007. doi:10.​1093/​jnci/​93.​13.​998 PubMedCrossRef
11.
go back to reference Hall SJ, Thompson TC (1997) Spontaneous but not experimental metastatic activities differentiate primary tumor-derived vs metastasis-derived mouse prostate cancer cell lines. Clin Exp Metastasis 15:630–638. doi:10.1023/A:1018499515883 PubMedCrossRef Hall SJ, Thompson TC (1997) Spontaneous but not experimental metastatic activities differentiate primary tumor-derived vs metastasis-derived mouse prostate cancer cell lines. Clin Exp Metastasis 15:630–638. doi:10.​1023/​A:​1018499515883 PubMedCrossRef
13.
go back to reference Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132:365–386PubMed Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132:365–386PubMed
14.
go back to reference Yonou H, Yokose T, Kamijo T, Kanomata N, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A (2001) Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 61:2177–2182PubMed Yonou H, Yokose T, Kamijo T, Kanomata N, Hasebe T, Nagai K, Hatano T, Ogawa Y, Ochiai A (2001) Establishment of a novel species- and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res 61:2177–2182PubMed
15.
go back to reference Tourkova IL, Yamabe K, Chatta G, Shurin GV, Shurin MR (2003) NK cells mediate Flt3 ligand-induced protection of dendritic cell precursors in vivo from the inhibition by prostate carcinoma in the murine bone marrow metastasis model. J Immunother (1997) 26:468–472CrossRef Tourkova IL, Yamabe K, Chatta G, Shurin GV, Shurin MR (2003) NK cells mediate Flt3 ligand-induced protection of dendritic cell precursors in vivo from the inhibition by prostate carcinoma in the murine bone marrow metastasis model. J Immunother (1997) 26:468–472CrossRef
16.
go back to reference Tourkova IL, Yamabe K, Foster B, Chatta G, Perez L, Shurin GV, Shurin MR (2004) Murine prostate cancer inhibits both in vivo and in vitro generation of dendritic cells from bone marrow precursors. Prostate 59:203–213. doi:10.1002/pros.10369 PubMedCrossRef Tourkova IL, Yamabe K, Foster B, Chatta G, Perez L, Shurin GV, Shurin MR (2004) Murine prostate cancer inhibits both in vivo and in vitro generation of dendritic cells from bone marrow precursors. Prostate 59:203–213. doi:10.​1002/​pros.​10369 PubMedCrossRef
18.
go back to reference Bloom RA, Libson E, Husband JE, Stoker DJ (1987) The periosteal sunburst reaction to bone metastases. A literature review and report of 20 additional cases. Skeletal Radiol 16:629–634. doi:10.1007/BF00357111 PubMedCrossRef Bloom RA, Libson E, Husband JE, Stoker DJ (1987) The periosteal sunburst reaction to bone metastases. A literature review and report of 20 additional cases. Skeletal Radiol 16:629–634. doi:10.​1007/​BF00357111 PubMedCrossRef
19.
go back to reference El Otmany A, Bouklata S, Hafid H, Chami I, Jalil A, Benjelloun S, Souadka A, Belabbas M (2000) Bone metastasis revealing a primary prostate cancer. J Radiol 81:990–991PubMed El Otmany A, Bouklata S, Hafid H, Chami I, Jalil A, Benjelloun S, Souadka A, Belabbas M (2000) Bone metastasis revealing a primary prostate cancer. J Radiol 81:990–991PubMed
21.
go back to reference Wyche LD, de Santos LA (1978) Spiculated periosteal reaction in metastatic disease resembling osteosarcoma. Orthopedics 1:215–221PubMed Wyche LD, de Santos LA (1978) Spiculated periosteal reaction in metastatic disease resembling osteosarcoma. Orthopedics 1:215–221PubMed
22.
go back to reference Henry MD, Silva MD, Wen S, Siebert E, Solin E, Chandra S, Worland PJ (2005) Spiculated periosteal response induced by intraosseous injection of 22Rv1 prostate cancer cells resembles subset of bone metastases in prostate cancer patients. Prostate 65:347–354. doi:10.1002/pros.20300 PubMedCrossRef Henry MD, Silva MD, Wen S, Siebert E, Solin E, Chandra S, Worland PJ (2005) Spiculated periosteal response induced by intraosseous injection of 22Rv1 prostate cancer cells resembles subset of bone metastases in prostate cancer patients. Prostate 65:347–354. doi:10.​1002/​pros.​20300 PubMedCrossRef
24.
go back to reference Chirgwin JM, Mohammad KS, Guise TA (2004) Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact 4:308–318PubMed Chirgwin JM, Mohammad KS, Guise TA (2004) Tumor-bone cellular interactions in skeletal metastases. J Musculoskelet Neuronal Interact 4:308–318PubMed
25.
go back to reference Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL (2002) Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 52:20–33. doi:10.1002/pros.10091 PubMedCrossRef Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL (2002) Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 52:20–33. doi:10.​1002/​pros.​10091 PubMedCrossRef
Metadata
Title
Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone deposition
Authors
N. Patrick McCabe
Maria Madajka
Amit Vasanji
Tatiana V. Byzova
Publication date
01-09-2008
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 5/2008
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-008-9175-1

Other articles of this Issue 5/2008

Clinical & Experimental Metastasis 5/2008 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine